about
Phase Transitions of Isotropic to Anisotropic Biocompatible Lipid-Based Drug Delivery Systems Overcoming Insoluble Benznidazole Loading.Antimicrobial activity of polymyxin-loaded solid lipid nanoparticles (PLX-SLN): Characterization of physicochemical properties and in vitro efficacy.An environmentally safe larvicide against Aedes aegypti based on in situ gelling nanostructured surfactant systems containing an essential oil.Structure and viscoelastic behavior of pharmaceutical biocompatible anionic microemulsions containing the antitumoral drug compound doxorubicin.Development and in vitro evaluation of surfactant systems for controlled release of zidovudine.Structural changes of biocompatible neutral microemulsions stabilized by mixed surfactant containing soya phosphatidylcholine and their relationship with doxorubicin release.The Monoglyceride Content Affects the Self-Assembly Behavior, Rheological Properties, Syringeability, and Mucoadhesion of In Situ-Gelling Liquid Crystalline Phase.Rheological Characterization and Safety Evaluation of Non-Ionic Lamellar Liquid Crystalline Systems Containing Retinyl Palmitate.Doxorubicin biocompatible O/W microemulsion stabilized by mixed surfactant containing soya phosphatidylcholineRelationship between structural features and in vitro release of doxorubicin from biocompatible anionic microemulsionStructural characterization and in vivo evaluation of retinyl palmitate in non-ionic lamellar liquid crystalline systemRheological, mechanical and adhesive properties of surfactant-containing systems designed as a potential platform for topical drug deliveryStructural and Thermal Behavior of Meglumine-Based Supra-Amphiphiles in Bulk and Assembled in WaterEvaluation of Microemulsion and Lamellar Liquid Crystalline Systems for Transdermal Zidovudine DeliveryMeglumine-based supra-amphiphile self-assembled in water as a skin drug delivery system: Influence of unfrozen bound water in the system bioadhesiveness
P50
Q37134303-660754D2-8F63-4B18-B9F9-B3A1D4B8C453Q38747706-3369AB5C-17B3-4123-B1A8-C1F3B1A06F85Q40149384-034A2EBC-03A1-450C-9525-CEF8B86644A9Q43172919-084B1D00-0622-4C19-91E5-554230F6B7BAQ43228225-1114797F-DAEF-4E93-9826-63398A9F7893Q46722986-CCF7FBCD-1A07-4EED-9A1A-8993F9CCEAA9Q51280621-A1670308-9303-4D7D-ABF6-125665B1B578Q54387439-EE1EC2B1-4E4D-4B41-A1A8-1829A012A06DQ79825781-1DFB0627-2B07-4F30-8F06-0615F1D0580BQ80574471-DFFAC920-9961-4225-837C-12D385165B35Q83630716-FBE0773C-E78E-4CA9-9587-978BCEA00081Q83928683-2F3D526D-E55C-4C4A-A4D9-F19A9CB818A3Q88630960-77F04C58-3DC1-4388-9E20-5246F59FF04AQ89274800-9EAD11A5-59D8-42D6-95E2-4B54781E79ADQ90849618-3BF1E4AD-AA70-4D61-B0DB-CAE571B49738
P50
description
investigador
@es
researcher
@en
name
Sarmento VH
@nl
Victor Hugo Sarmento
@en
type
label
Sarmento VH
@nl
Victor Hugo Sarmento
@en
altLabel
Sarmento VH
@en
prefLabel
Sarmento VH
@nl
Victor Hugo Sarmento
@en
P31
P496
0000-0001-6882-002X